Profile of maraviroc: a CCR5 antagonist in the management of treatment-experienced HIV patients
Maraviroc is the first and, so far, the only licensed representative of the class of chemokine receptor type 5 (CCR5) inhibitors used for the treatment of human immunodeficiency virus (HIV) infection. Its safety and efficacy were demonstrated in several clinical trials, and its use was approved in 2...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2010
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218686/ |